The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

Mamas Mamas, Ruben de Winter, and Paul Knaapen discuss the results of the PROCTOR trial, which explored native vessel versus ...

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.